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FATTY ACID REQUIRED FOR GLUCOSE-INDUCED CHANGE IN BETA CELL 
PLASMA MEMBRANE POTENTIAL LEADING TO INSULIN SECRETION 
RONALD ALLEN 
ABSTRACT 
 The pancreatic β−cell secretes insulin through a combination of triggering 
and amplification pathways in response to glucose.  Glucose metabolism is 
known to increase intracellular calcium and trigger insulin secretion from the 
β−cell while fatty acid (FA), an essential component of glucose stimulated insulin 
secretion (GSIS), is known to amplify secretion through varied mechanisms.  
Orlistat, a lipase inhibitor, blocks GSIS although the mechanism has not been 
clearly elucidated.  We show that orlistat can also inhibit basal insulin secretion. 
FA can prevent/reverse orlistat-induced inhibition of secretion but fails to amplify 
GSIS after orlistat treatment. Here we test the hypothesis that FA is required to 
maintain normal plasma membrane potential and calcium influx in the β−cell.  
Clonal pancreatic β−cells (INS-1 832/13) were cultured in RPMI media containing 
11 mM glucose and 10% FBS.  Insulin secretion was measured over 2 hours with 
and without FA and orlistat (200 µM) using homogeneous time resolved 
fluorescence insulin assay (HTRF, Cisbio) and reported as ng/million cells.  
Intracellular calcium was measured in single cells using fura-2 AM. Single cell 
membrane potential was measured with virally expressed ARC Lite protein 
(Montana molecular). High glucose (8 mM) stimulated insulin secretion at least 3-
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fold over basal glucose (2 mM) and addition of FA enhanced GSIS. Orlistat 
almost completely abolished GSIS.  This inhibition was mostly prevented in the 
presence of FA.  Orlistat blocked calcium influx required for triggering insulin 
release while addition of FA recovered normal calcium homeostasis. The 
monoacylglycerol lipase inhibitor JZL 184 reduced both calcium influx and the 
increase in plasma membrane potential induced by KCl. FA recovered plasma 
membrane potential inhibited by JZL 184. Our results suggest that reducing 
β−cell intracellular FA availability by lipase inhibition blocks GSIS by preventing 
the glucose-induced rise in plasma membrane potential required to induce β−cell 
calcium influx through voltage dependent calcium channels (VDCC).  FA is thus 
required to maintain normal nutrient metabolic coupling to insulin secretion. 
Whether the effect of FA to modulate plasma membrane potential plays a role in 
β−cell insulin hypersecretion resulting from excess nutrients requires further 
investigation.  
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INTRODUCTION 	
Type 2 diabetes mellitus (T2DM) 
Type 2 diabetes mellitus (T2DM) is a disease affecting over 30 million Americans 
and the 7th leading cause of death in the United States (1).  It is a chronic lifelong 
disease that affects protein, carbohydrate, and fat metabolism and is caused by 
either a defect in insulin signaling in the peripheral tissue (insulin resistance) or a 
defect of insulin secretion from the pancreatic β−cell in the islet of Langerhans 
(β−cell dysfunction). The primary pathogenesis in the development of T2DM is 
based on β−cell dysfunction causing the inability to control blood glucose.  
Prolonged elevated blood glucose levels can lead to organ failure, vision loss, 
and many other serious health problems.  To date, diabetes is the leading cause 
of kidney failure, limb amputations, and adult on-set blindness (1).  Obesity, also 
a condition affecting millions worldwide, has a strong relation to insulin resistance 
and diabetes.  In obese individuals, factors involved in insulin resistance such as 
nonesterfied fatty acids (NEFAs), cytokines, and glycerol are all increased (24).  
However, not all obese individuals are insulin resistant nor are all insulin resistant 
individuals obese (33).  This leaves to question the cause of factors leading to 
diabetes.  In earlier years it was hypothesized that the β−cell, in response to 
insulin resistance, compensates and secretes more insulin required to maintain 
normal blood glucose levels, also known as β−cell insulin hypersecretion (IH).  In 
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this theory, IH is a result of insulin resistance.  However, there is no satisfactory 
explanation of how insulin resistance might stimulate insulin secretion. 
More recently it has been proposed that IH can contribute to the onset of insulin 
resistance (33). It is known that the same metabolic signals that produce insulin 
resistance in muscle can result in a left-shift in the glucose-dose response for 
insulin secretion from the β−cell resulting in an increase in basal insulin secretion 
(34). This impaired insulin secretion occurs in β−cell culture models including 
clonal cells (INS-1) and isolated rat islets and is thus an effect on the β−cell itself 
and not dependent on insulin resistance from other tissues. It has been proposed 
that this increased basal insulin release can give rise to hyperinsulinemia, which 
can induce insulin resistance in peripheral tissues (35).   
Glucose-stimulated insulin secretion (GSIS) 
Triggering 
Glucose is the main driver of insulin secretion from the β−cell.  Glucose enters 
the β−cell through the GLUT1 (GLUT2 in mice) transporter where it enters 
glycolysis or the pentose phosphate pathway (22).  Increased flux through 
glycolysis and the TCA cycle raises the NADH/NAD ratio in the mitochondrial 
matrix providing reducing agents for the electron transport chain ultimately 
increasing O2 consumption and ATP synthesis (12). We determined that ROS 
could directly stimulate insulin secretion (43,44). We also found that increasing 
the mitochondrial redox state (NADH/NAD) increased both ROS generation and 
insulin secretion (43).  The increase in the cytostolic ATP/ADP ratio causes ATP-
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sensitive K+ (KATP) channels to close (12).  Closure of this channel causes 
membrane depolarization, opening VDCC, and Ca2+ influx into the cytoplasm 
(11).  The rise in intracellular Ca2+, sensed by multiple Ca2+ binding proteins, 
triggers insulin granule exocytosis from the β−cell (11).  This classical pathway, 
appropriately termed the GSIS “triggering pathway”, is dependent on the KATP-
channel(11)(12).  
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Figure 1. Model of glucose-induced and FA amplified insulin secretion. 
Triggering.  Glucose enters the β−cell through the GLUT2 transporter where it 
enters the glycolysis cycle.  Increased flux through glycolysis and the TCA cycle 
raises the NADH/NAD ratio in the mitochondrial matrix ultimately leading to ATP 
synthesis.  The increase in the cytostolic ATP/ADP ratio causes ATP-sensitive 
K+ (KATP) channels to close.  Closure of this channel results in membrane 
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depolarization due to the inward K+ current through Kir channel.  Membrane 
depolarization opens VDCC and causes a rise in Ca2+ into the cytoplasm that 
triggers insulin granule exocytosis.  Calcium oscillations also activate PKC  
leading to insulin granule exocytosis. 
Amplification. FFA bind to the GPR40 receptor and activate PLC through a 
coupled G protein, Gαq. PLC hydrolyzes PIP2 to produce IP3 and DAG.  IP3 
binds to receptors of the endoplasmic reticulum and causes Ca2+ release and 
oscillations. DAG binds and activates PKC and PKD1 leading to insulin 
exocytosis.   DAG also binds MUNC-13 that directly interacts with the exocytotic 
machinery of insulin. 
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Amplification 
The next phase, occurring independently of the KATP-channel but still closely 
linked to the triggering phase, is known as the GSIS “amplification phase”.  This 
is an important phase as it in comparison to the triggering phase, accounts for 
85% of the total insulin secretion within a 1 hour stimulation (15).  In this phase, 
GSIS is enhanced via free fatty acids (FFA) and other metabolites linked to 
glucose metabolism such as ATP and malonyl CoA (14).  These metabolites act 
as metabolic coupling factors (MCF) in the GSIS amplifying pathway.  Lipids 
generated or mobilized downstream of glucose stimulation can influence the 
metabolic amplifying pathway through intracellular targets or possibly by exiting 
the cell and activating receptor-mediated mechanisms of amplification (16).  
Conversely in the fasted state, when FFA levels are at their highest, FFA are 
coverted to acyl-CoA by acyl-CoA synthase in the cytoplasm and transferred into 
the mitochondria for oxidation via carnitine palmitoyl transferase 1 (CPT1).  
Stimulation of β−cells with glucose induces changes in the concentrations of a 
variety of intracellular lipids, including monoacylglycerol (MAG) and diacylglycerol 
(DAG). MAG and DAG levels are regulated by DAG and MAG lipases that are 
responsible for the final steps of triacylglycerol catabolism (DAG à glycerol + FA 
+ MAG à glycerol + FA) as well as other lipases that contribute to GSIS such as 
phospholipase C (PLC) (5). We previously reported that pharmacologically 
inhibiting MAG lipase (MAGL) in the cytoplasm inhibited biphasic insulin 
	7	
	
secretion and both the triggering and amplifying pathways in rat islets.  This 
study proposed that maintaining proper concentrations of MAG in specific 
compartments is important since a build-up of MAG during MAGL inhibition may 
contribute to the blunting of GSIS (6). These findings suggest that MAG is a 
required secretory molecule for insulin secretion. In this same study, inhibition of 
MAGL reduced cytostolic long-chain acyl-CoA (LC-CoA) possibly because of 
reduced fatty acid availability, which may have contributed to the inhibition of 
insulin secretion.  
Long-chain acyl-CoA (LC-CoA) 
Glucose metabolism leads to a putative increase in cytosolic LC-CoA in the 
β−cell (36). Via passive diffusion (flip flop) of elevated extracellular FFA enters 
the cytoplasm where it can be converted to Long-chain acyl-CoA by long-chain 
acyl-CoA synthetase (ACSL). Malonyl-CoA inhibits carnitine-palmitoyl 
transferase 1, which is responsible for the transfer of FA to the mitochondria to 
be oxidized (22). Thus glucose metabolism inhibits FA oxidation, allowing for an 
increase in cytosolic LC-CoA. LC-CoA has been shown to affect multiple 
processes influencing insulin secretion including 1) Ca2+ homeostasis (18)  2) 
KATP-channel activity (31)  3) PKC activity (23)  4) protein acylation and insulin 
exocytosis (29). It is known that FA is required for insulin secretion. Studies have 
shown that inhibiting lipolysis in rats prevents insulin secretion (32). When islets 
from these rats were studied ex-vivo secretion was recovered by the exogenous 
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addition of FFA.  The mechanism of FA recovery of insulin secretion is not 
known. 
Lipase inhibition with orlistat  
Orlistat is a non-specific lipase inhibitor. An earlier study, indicated that orlistat 
effectively inhibited insulin secretion stimulated by forskolin, an activator of 
adenylate cyclase, which increased cAMP and lipolysis (13).  In this same study 
it was shown that orlistat inhibited GSIS as well, supporting a model where 
intracellular fatty acids likely participate in the insulin exocytotic process. Addition 
of FA was able to prevent the inhibition of secretion induced by orlistat. The 
authors claimed that GSIS was completely recovered by the addition of FA in this 
case. The problem with their claim was that these authors ignored the fact that 
FA should increase GSIS, a control that they failed to show. Thus in their studies, 
a full recovery of GSIS was only a partial recovery of the secretion inhibited by 
orlistat. A component of secretion that was never recovered was the potentiation 
of GSIS by FA.  In addition a mechanism of inhibition was not tested. 
Failure of FA to completely recover insulin secretion in the presence of orlistat 
could be due to impaired phospholipase C (PLC) activity. One of the known G 
protein-coupled receptors (GPCRs) known to receive signals from fatty acids is 
GPR40. GPR40 is a long-chain fatty acid receptor, which may enhance glucose-
induced amplification of insulin secretion via IP3-Ca2+ and DAG-PKC/PKD1 
pathways (7).  FFA bind to the GPR40 receptor and activate phospholipase C 
(PLC) through a coupled G protein. PLC is responsible for hydrolyzing PIP2 to 
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produce IP3 and DAG (39).  IP3 binds to receptors of the endoplasmic reticulum 
and causes Ca2+ release to increase intracellular concentration (39).  DAG binds 
and activates PKC and PKD1 (9) (10).   In addition, DAG binds MUNC-13; a 
protein that directly interacts with the exocytotic machinery to regulate GSIS (45). 
The exocytotic protein Syntaxin is bound to MUNC-13 and released upon DAG 
binding to stimulate exocytosis (5)(45). 
Aim 
To further investigate the role of FA in β−cell insulin secretion we utilized lipase 
inhibitors, Orlisat and JZL 184, and observed the plasma membrane and Ca2+ 
influx that was associated with GSIS.  We hypothesize that the glycerolipid/free 
FA cycle (GL/FFA) regulates GSIS through FFA lipid signaling enabling plasma 
membrane potential and subsequent voltage gated channel activity to regulate 
Ca2+ influx. In addition, we attempted to determine whether GPR40 activation of 
PLC activity produced lipid signals other than FA that could explain the inability of 
FA to recover all of the effect of orlistat on insulin secretion. 
MATERIALS AND METHODS 
Reagents 
Culture media: RPMI 1640 with phenol red containing 11 mM glucose, 10 mM 
HEPES, 2 mM glutamine, 1 mM sodium pyruvate, 50 IU/mL penicillin and 50 
µg/mL streptomycin (PS), 10% fetal bovine serum (FBS) and 50 µM β-
mercaptoethanol (BME).  
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Pre-incubation media: RPMI 1640 with phenol red containing 2 mM glucose (2G), 
10 mM HEPES, 1 mM sodium pyruvate, 50 IU/ml penicillin, 50 µg/mL 
streptomyocin, and 2 mM glutamine.  
Krebs Ringer Bicarbonate buffer (KRB): 119 mM NaCl, 4.6 mM KCl, 5 mM 
NaHCO3, 2 mM CaCl2, 1 mM MgSO4, 0.15 mM Na2HPO4, 0.4 mM KH2PO4, 20 
mM HEPES, 0.05% BSA, and pH 7.4.  
Phosphate buffered saline/ehtylenediamine tetra-acetic acid (PBS/EDTA): 
solution contained PBS (Sigma, St. Louis, MO) and 0.2g EDTA, pH 7.4.  
Transduction media: containted 50% Bacman Stock virus (Montana Molecular), 
47% PBS, and 3% 500 mM Na-butyrate. 
Cell culture 
INS-1 832/13 cells were cultured in RPMI media (described above) at 37°C in a 
humidified atmosphere containing 5% CO2/95% air and were used from passage 
50-80. The feeding media were discarded and reapplied every 48 hours during 
culturing. Cells were grown until confluent and passaged once a week.  To 
passage, cells were first washed with PBS/EDTA and then incubated in trypsin 
(0.005%) in PBS/EDTA for 2 minutes.  Trypsin was removed and the culture 
media was then applied to wash the cells off the flask.  From this cell solution, 
total number of cells was counted using a hemocytometer.  The average cell 
number from each 16 block corner of the hemocytometer was multiplied by 
10,000 to yield cells /ml of the cell suspension.  A series of calculations were 
done to determine the amount of cells needed to plate for each experimentbased 
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on the cell doubling time and days in culture.  INS-1 cells were grown for at least 
4 days (96 hours) and doubled in number every 32 hours (96 ÷ 32 = 3) so the 
cells doubled three time in culture. 0.2 million cells/well in 48-well plates were 
need for experiments.  Cells were plated in 0.5 ml/well. The amount of cells 
needed per 0.5mL was determined by dividing 0.2 million by 23 (0.2 ÷ 23 = 0.025), 
yielding 25,000 cells/0.5 ml or 50,000 cells/ml. The cell number counted on the 
hemocytometer was divided by 0.05 million cells/ml to determine the dilution of 
the cell suspension required to plate 25,000 cells/well in a 48-well plate for 4 
days. 
Insulin secretion 
On the day of experiment, cells were pre-incubated with RPMI containing 2 mM 
glucose without FBS, PS and BME for 2 hours at 37°C in the 5% CO2 incubator.  
The preincubation media were then discarded and a low glucose Krebs Ringer 
Bicarbonate buffer (KRB) preincubation containing 2 mM glucose and 0.05% 
bovine serum albumin (BSA) was added and the plate was placed in a 37°C pre-
heated waterbath for 30 minutes.  The plate was then cooled on ice for 5 min.  
The KRB preincubation was discarded and KRB test solutions were added 
containing 0.05% BSA, various concentrations of glucose, with or without orlistat 
and fatty acid (FA).  FA was added as an oleate:BSA complex.  Cells were 
incubated for 2 hours at 37°C. Supernatants from each well were collected and 
the insulin concentration was measured using homogeneous time resolved 
fluorescence (HTRF) insulin assay (Cisbio). 
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FA oleate:BSA complex preparation 
The oleate:BSA complex was made from a 3.15 M stock solution of oleate. After 
thawing 12.69 µl of stock oleate was combined with 187.31 µl of DMSO to make 
a 200 µl working solution and placed in a 55 0C waterbath.  A 50 ml conical tube 
containing 10 ml of 6.7% BSA KREBS buffer was also mixed in a separate tube 
and place in the watherbath.  When both tubes were 55 0C, 20 µl of the 
oleate/DMSO mixture was added while vortexing to the 50 ml conical tube 
containing 10 ml of 6.7% BSA.  This was repeated 5X until 100 µl of the FA was 
mixed with in the buffer. The final molar ratio concentration of the FA:BSA 
complex is 3.3 which is 2 mM FA in 4% BSA.  
 
Lipase inhibitor preparations 
orlistat (Sigma, St. Louis, MO) and JZL184 (Cayman Chemical, Ann Arbor, MI) 
were resuspended in DMSO and stored as stocks. For experiments stocks were 
diluted into KRB at 37°C while vortexing. The final concentration of orlistat and 
JZL 184 varied in separate experiments. 
Intracellular Ca2+ measurement 
Intracellular Ca2+ was measured in INS-1 cells using the cell permeant 
fluorescent Ca2+ dye fura-2 AM (Thermo Fisher).  INS-1 cells were cultured in 35 
mm glass bottom dishes prior to experiments and then rested in 2 mM glucose 
RPMI without FBS for 2 hours followed by a 30-minute incubation in 2 mM 
glucose KRB with 2 µM fura-2 AM and 0.1% pluronic acid (Thermo Fisher). Cells 
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were then loaded with fura-2 AM.  After loading, cells were incubated for 15 
minutes in KRB without fura-2 AM to complete cleavage of the loaded fura-2 AM 
ester prior to mounting onto the stage of an Olympus DSU spinning disk 
microscope. A stage chamber maintained a 37°C temperature throughout the 
experiment. Fluorescence images were obtained at 20X magnification every 10 
seconds with excitation wavelengths of 340 and 380 nm and dual emission of 
510 nm. 
Plasma membrane potential 
Plasma membrane potential was measured in INS-1 cells using virally expressed 
ARC-light protein (Molecular Montana).  Cells were cultured in 35 mm glass 
bottom dishes containing 33% transduction solution and 67% normal media.  The 
plate was placed in an incubator (5% CO2 and 37°C) for overnight.  The solution 
was then aspirated and replaced with feeding media containing 1-2 mM Na-
Butyrate.  Cells were then allowed to grow for 24 hours before measuring 
fluorescence.  
Experiments were performed similar to those for Ca2+ measurements. Cells were 
mounted onto the stage of an Olympus DSU spinning disk microscope. A stage 
chamber maintained a 37°C temperature throughout the experiment. 
Fluorescence images were obtained at 20X magnification every 10 seconds with 
an excitation wavelength of 480 and emission wavelength of 525 nm. 
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RESULTS 
 
Orlistat reduced GSIS and Fatty Acid recovered 
The effect of lipase inhibition on GSIS was determined using orlistat, a pan-
inhibitor that acts via formation of a covalent bond to a serine in the lipase active 
site (20). A single glucose stimulation protocol was used in this and other 
experiments.  Extracellular solution containing 2 mM glucose was used as the 
control non-stimulatory condition while raising the glucose concentration to 8 mM 
served to stimulate insulin secretion from the INS-1 cells.  Over a 2 hour 
incubation period, acute stimulation with glucose increased insulin secretion by 
approximately 3-fold. Addition of 200 µM oleate (FA) further increased GSIS by 
almost 2-fold without increasing basal secretion. GSIS was inhibited by 75% 
when cells were treated with orlistat (200 µM) (Fig 2).  This orlistat dosage was 
used for maximum inhibition of lipases.  Addition of 200 µM oleate to INS-1 cells 
and orlistat resulted in normal GSIS, but failed to enhance GSIS as would 
normally occur in the absence of orlistat. Neither FA or orlistat caused a 
significant change in basal insulin secretion although this was not the case in 
20% of experiments. 
Occasionly, it was also observed that orlistat would reduce insulin secretion from 
INS-1 cells even under low basal glucose conditions.  200 µM orlistat inhibited 
basal insulin secretion by 50% in the experiment shown in Figure 3. Addition of 
FA with orlistat prevented the observed inhibition of basal insulin secretion. 200 
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µM oleate does not normally stimulate insulin secretion under low glucose basal 
conditions (Fig 2 and Fig 3).  The clear decrease in basal insulin secretion due to 
orlistat exposure shown in Figure 3 seems to indicate that basal insulin secretion 
can be regulated by FA under some conditions. The mechanism of this orlistat 
inhibition of basal secretion is under investigation. 
 
 
Figure 2. Orlistat reduces GSIS and FA recovers. High glucose (8 mM (red 
bars)) stimulated insulin secretion at least 3 fold over basal  low glucose (2 mM 
(blue bars). Addition of 200 µM oleate (FA) increased GSIS almost 2-fold. 200 
µM orlistat (OR) inhibited GSIS by 75%, which was recovered to the control level 
by addition of FA in INS-1 cells (FAOR), however not to the level achieved with 
glucose + FA.  Results are the average of 4 replicates in 1 experiment. 
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\ 
 
 
Figure 3. An experiment where orlistat reduces basal insulin secretion and 
FA recovers. Basal insulin secretion measured at 2 mM glucose (control) was 
inhibited by 50% with orlistat (200 µM) (OR). Oleate (200 µM) addition recovered 
basal secretion inhibited by orlistat (ORFA). Oleate did not stimulate basal 
secretion in the absence of orlistat (FA). Results are representative of single 
experiment.  Similar results were obtained in 4 out of 20 experiments. 
 
Orlistat blocked Ca2+ influx associated with GSIS and FA recovered 
Since orlistat was so effective at inhibiting GSIS we tested whether Ca2+ influx, 
one of the final steps in exocytosis, was also blocked. Figure 4A, displays a 
respresentative intracellular Ca2+ trace showing the effects of glucose, orlistat, 
and FA on Ca2+ influx in INS-1 cells.  β−cells display little oscillatory activity in the 
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low 2 mM glucose starting condition, but are activated in response to stimulation 
with high glucose (21).  Glucose was increased from 2 mM to 8 mM at 
approximately 500 seconds.  Four minutes later (approx. 750 seconds) a typical 
oscillatory pattern of intracellular Ca2+ develops within the clonal β−cell. This 
increase is the result of glucose metabolism increasing the intracellular ATP/ADP 
ratio, depolarizing the plasma membrane and opening voltage gated Ca2+ 
channels allowing for Ca2+ influx. Orlistat exposure to the INS-1 cells at 1200 
seconds reduced Ca2+ oscillations.  At 1900 seconds oscillations are resumed by 
treating cells with FA.   
Figure 3B shows the average intracellular signal from 10 cells in a single 
experiment. In this case, Ins-1 cells were stimulated with a combination of 8 mM 
glucose and 30 mM KCl in the presence of 250 µM diazoxide (DZ). DZ prevents 
ATP dependent closure of the KATP-channel and thus decouples glucose 
metabolism from them membrane depolarization and Ca2+ entry through VDCC.  
Orlistat was also effective in inhibiting Ca2+ influx under these select conditions 
suggesting that the inhibition was independent of glucose metabolism. Together 
these results show that there is a range of lipid composition and or lypolitic 
activity that supports Ca2+ homeostasis in the β−cell.  
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A 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
Figure 4. Orlistat inhibits Ca2+ oscillations and FA recovers. A. Typical trace 
of Ca2+ oscillations from a single INS-1 cell treated with orlistat.  Arrows indicate 
point of application of 8 mM glucose (G), 200 µM orlistat (OR), and 200 µM 
  OR 
   FA 
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oleate 4:1 (FA).  Trace started with cells in 2 mM glucose. orlistat inhibited 
glucose-induced Ca2+ oscillations (1200 sec), which was recovered by FA (2000 
sec). Typical results from a single oscillating cell shown.  n = 2 separate 
experiments. B. orlistat inhibits depolarization-induced Ca2+ increase and is 
recovered by FA in INS-1 cells. Average of 7 cells.  n = 3 separate experiments.  
 
JZL 184 reduced glucose and depolarization-induced Ca2+ oscillations  
Given our discovery that lipase inhibition reduces Ca2+ influx, it was important to 
determine the associated GSIS process affected that may be the cause of the 
reduction.  Since one of the main sources of Ca2+ influx is via VDCC that is 
dependent on membrane depolarization, we investigated the relationship 
between lipase inhibition and plasma membrane potential.   
To ensure that these results were not exclusive to inhibition with orlistat, we used 
the monoacylglycerol lipase inhibitor JZL 184 to specifically inhibit MAG lipolysis 
and therefore intracellular FA (MAG à FA + Glycerol).  As shown in Figure 5A, 
raising the concentration of glucose increased intracellular Ca2+ as indicated by 
the fura-2 AM ratio, but in the presence of JZL 184 this signal was reduced.  This 
is consistent with the reduction of intracellular Ca2+ observed with lipase 
inhibition by orlistat (Fig 4A). KCl was then added to depolarize the cell and open 
voltage gated channels to stimulate Ca2+ influx. While the control cells showed a 
robust increase in intracellular Ca2+, the response was almost completely absent 
in cells treated with JZL 184.  DZ again was used to decouple glucose 
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metabolism from insulin secretion by preventing ATP dependent closure of the 
KATP-channel (Fig. 5B). JZL 184 was also effective in inhibiting Ca2+ influx under 
these select conditions suggesting that the inhibition was independent of glucose 
metabolism. 
 
A 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
Figure 5. JZL 184 inhibits glucose-induced Ca2+ oscillations (A) and 
depolarization-induced Ca2+ increase (A and B). Time trace of intracellular 
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Ca2+ in aINS-1 cells in a single experiment.  Arrows indicate points of application 
of glucose (G), JZL 184, and KCl.  Cells were stimulated with 12 mM glucose and 
30 mM KCl in both A and B.  A. JZL 184 inhibited both glucose dependent 
oscillations and depolarization-induced Ca2+ jnflux. Results are the average of 2 
separate experiments.  B. JZL 184 inhibited depolarization-induced Ca2+ jnflux 
(15 minutes) in the presence of 250 µM DZ.  n = 3 separate experiments. 
 
Blocking lipolysis prevents plasma membrane depolarization 
 
To further investigate the changes in GSIS and intracellular Ca2+ induced by 
decreased lipase activity, we resorted to ArcLight sensor fluorescence.  The 
ArcLight sensor is a genetically-encoded fluorescent voltage sensor that is virally 
delivered into the plasma membrane of the INS-1 cells.  The sensor undergoes 
shifts in fluorescence intensity in response to voltage changes in the plasma 
membrane (25).  It is important to note that in figure 6 an increase in plasma 
membrane potential and thus fluorescence is shown as a decrease on the x-axis 
of the graph.  Diazoxide application at the start of the experiment was used to 
maintain the KATP-channel open and thus the membrane potential was held at a 
resting state. KCl, administered at 1 min, increased intracellular K+ and 
depolarized the cells.  JZL 184 was shown to repolarize the plasma membrane 
following KCl-induced depolarization indicating that reducing intracellular FA 
lowers the plasma membrane potential.  Addition of FA allows the cell to recover 
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the depolarization induced by KCL. Results suggest that FA can regulate K+ flux 
across the plasma membrane to affect plasma membrane potential. The 
mechanism of FA regulation of plasma membrane potential is still under 
investigation. 
 
Figure 6. JZL hyperpolarizes INS-1 cell plasma membranes in the presence 
of KCl and DZ and FA recovers membrane depolarization. Arrows indicate 
points of application of DZ, KCl, JZL 184, and FA. KCl depolarizes the plasma 
membrane indicated by a decrease in the fluorescence of the membrane 
potential sensor ArcLight. JZL 184 repolarizes and 200 µM oleate (FA) recovers 
the depolarized state of the β−cell. Results are average fluorescence from 5 
single cells imaged in a single experiment. 
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DISCUSSION 
 
In this thesis we explored mechanisms to further elucidate the role of FA in 
normal GSIS. To do this we inhibited lipolysis to limit the availability of FA 
generated from intracellular stores, the largest of which is triglyceride containing 
lipid droplets. The lipase inhibitor, orlistat, reduced GSIS by at least 75%.  Basal 
insulin secretion could also be inhibited occasionally. Orlistat and the 
monacylglycerol inhibitor JZL 184 both prevented normal Ca2+ influx when ß-cells 
were stimulated with glucose and/or KCl. The effect of JZL 184 to block Ca2+ 
influx was shown to be due to an effect on cellular plasma membrane potential. 
Thus FA, which is normally thought to amplify insulin secretion, is now also 
shown to be inextricably linked to the triggering pathway of insulin secretion. 
In the past, investigators have used lipase inhibition as a way to determine the 
contribution of FA released from intracellular stores in the amplification of GSIS 
(13). This was done in part to try to dissect the triggering and amplification 
pathways of exocytosis. Our results demonstrate that the penultimate steps in 
regulation of Ca2+ influx associated with insulin secretion in fact require at least 
some threshold level of FA. Thus inhibition of FA production leading to impaired 
insulin secretion should not be attributed to impaired amplification unless 
intracellular Ca2+ has been shown to be unaffected. 
The link between triggering and amplification pathways of secretion is highlighted 
in our studies using orlistat to inhibit lipolysis. We find the major inhibitory effect 
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of orlistat is to prevent depolarization and block Ca2+ influx into the ß-cell 
resulting in reduced insulin secretion. Addition of FA recovers plasma membrane 
potential, Ca2+ influx and secretion. Secretion however is only recovered to the 
level of GSIS in the control and does not match the level of secretion stimulated 
by glucose plus FA.  
Thus it seems that the triggering path of insulin secretion is recovered while 
amplification of release is still impaired. This continued impairment could be due 
to the loss of a product of lipase activity other than FA. FA is known to bind to the 
GPR40 receptor coupled to G-protein activation of PLC. PLC is a lipase that 
produces secondary messengers, IP3 and DAG, from PIP2 hydrolysis at the ß-
cell plasma membrane (39). DAG generated in this way can then bind to MUNC-
13 in the exocytotic machinery to stimulate insulin release (45). Orlistat inhibition 
of PLC activity may decrease DAG production from PIP2 to a level below the 
threshold to amplify GSIS.  
It is interesting that orlistat can in some cases even lower basal insulin secretion. 
Excess nutrient exposure leads to glucolipotoxicity (GLT) in the ß-cell 
characterized by decreased GSIS and increased basal insulin secretion. We 
recently reported that GLT causes a left-shift in the glucose dose response for 
insulin secretion from pancreatic ß-cells that may contribute to increased basal 
secretion (2). The cells used in these experiments were cultured in RPMI with 11 
mM glucose and thus have high lipid stores as indicated by the presence of 
intracellular lipid droplets (2). Thus PLC activity and DAG production in these 
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cells could reach levels that are stimulatory for basal insulin release. Orlistat 
could thus reduce basal insulin secretion in these cells exposed to excess 
nutrients by decreasing PLC activity and DAG. Whether orlistat inhibits PLC 
activity to the point of reducing the levels of DAG below a threshold required to 
increase basal or amplify GSIS is under investigation. 
Alternatively, it may be that increased basal insulin release is due to an increase 
in the number of ß-cells with increased Ca2+ oscillations at inappropriately low 
glucose exposure. The increased number of ß-cells exhibiting this 
hypersensitivity to glucose could result in increased basal secretion compared to 
controls cells with less FA stores. The ability of orlistat to reduce basal insulin 
secretion in this case would be due to its effect to collapse the plasma membrane 
potential and close voltage gated Ca2+ channels, effects that are reversed with 
addition of exogenous FA. 
FA and other lipid molecules in the pancreatic β−cell help regulate many cellular 
functions including Ca2+ homeostasis and insulin exocytosis.   FAs are also 
known to have the capacity to amplify GSIS, which is particularly operative in the 
situation of	β-cell compensation for insulin resistance.  Thus, GSIS is potentiated 
by FA in various pathways. In this study, we propose that one of the pathways for 
FA augmentation of GSIS is via regulation of plasma membrane potential.  Due 
to the close relation between plasma membrane potential and VDCC activity, it is 
essential to study mechanisms that control or modulate ß-cell membrane 
potential.  
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Inwardly rectifying K+ channels (Kir) can be considered equally important as KATP-
channels for membrane potential.  At substimulatory glucose concentrations, 
KATP-channels are open, allowing K+ efflux out of the β−cell.  Concurrently, Kir 
channels allow a small inward K+ current inside the cell, maintaining a negative 
resting membrane potential (40).  When KATP-channels are closed and K+ efflux 
is reduced, the inward current via Kir channels increases membrane potential 
and causes membrane depolarization.   
Membrane phosphoinositide, phosphatidylinositol-4,5-bisphosphate (PIP2), has 
also been shown to directly regulate Ca2+ channels in the plasma membrane by 
stimulating KATP-channels (30). The presence of PIP2 in the β-cell 
plasma membrane has been found to stimulate the KATP-channel and have a 
hyperpolarizing effect by decreasing the channel sensitivity to ATP (26).  Thus 
increase of PIP2 in the plasma membrane rendered INS-1 cells hyperpolarized 
and unable to secrete insulin in the face of high glucose.  Adequate levels of PIP2 
levels are also necessary for cytoskeleton rearrangement and priming of insulin 
granules (30).   
Early studies found that LC-CoA also increased KATP-channel activity, 
characterized by openings of long duration and membrane repolarization (31).  
This was found to be caused by a conformational change of the KATP-channel 
protein induced by LC-CoA binding (32).  This means that the accumulation of 
LC-CoA is able to counteract the blocking effect of ATP on the KATP-channel 
produced by glucose metabolism preventing membrane depolarization and 
	27	
	
opening of VDCC.  Interestingly, this LC-CoA effect is specific for the KATP-
channel and does not hold for other K+ channels in the plasma membrane (40).  
In other Kir channels LC-CoA is known to inhibit activity, blocking inward K+ flow, 
causing the β−cell to be in a hyperpolarized state and unable to secrete insulin 
(40). 
The studies mentioned above described conditions of nutrient excess that 
prevented GSIS as is the case with hyperglycemia, glucolipotoxicity, and T2DM.  
The conditions are similar to elevated circulating blood glucose observed in 
diabetic subjects.  Thus the levels of FA circulating in blood may then have an 
effect on resting plasma membrane potential altering the increase needed to 
reach threshold required for depolarization and insulin secretion.  
To definitively establish that FA accumulation lowers plasma membrane 
potential, a direct measurement of plasma membrane potential is required, 
possibly via voltage clamp techniques.  This would provide measurements of 
plasma membrane potential before and after lipase inhibition, activation time 
constants and determine if these changes affect the ability of stimulatory glucose 
concentrations that depolarize the ß-cell to threshold levels leading to insulin 
release.  This method is also reliable because it does not depend on 
fluorescence. To confirm the accuracy of our fluorescence experiments and to 
ensure that JZL 184 is not quenching (Fig 4), future tests should permeabilize 
cells expressing ARCLight voltage sensor and then add JZL 184.  This maneuver 
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will keep a constant membrane potential due to having the same ions on both 
sides of the membrane.   
In conclusion, these results suggest lipase inhibition prevents glucose-stimulated 
release of insulin by preventing plasma membrane potential depolarization.  In 
addition to earlier studies of nutrient excess, this study of lipase inhibition 
strongly suggests a prominent role of FA in the β−cell nutrient sensing apparatus 
and adds further support to the hypothesis that a controlled lipid environment is 
obligatory in nutrient-stimulated insulin secretion.  
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